FIRST Study Shows Lenalidomide Plus Dexamethasone Safe and Effective for Multiple Myeloma
the Cancer Therapy Advisor take:
According to final results from the phase 3 FIRST study published in the New England Journal of Medicine, continuous lenalidomide (Revlimid) plus dexamethasone was safe and effective for the treatment of patients with newly diagnosed multiple myeloma who are not eligible to receive stem cell transplantation.
In the study, researchers found that those treated with continuous oral lenalidomide in combination with low-dose dexamethasone (Rd) had a progression-free survival (PFS) of 25.5 months while those treated with a fixed course of lenalidomide plus low-dose dexamethasone (Rd18) had a PFS of 20.7 months. Those treated with melphalan, prednisone, and thalidomide (MPT) had a PFS of 21.2 months.
Therefore, those treated with Rd had a 28% decrease in risk of progression of disease or death compared with those treated with Rd18 (P<0.001) and a 30% reduction compared with those treated with Rd18 (P<0.001).
The most common adverse effects observed with Rd therapy were infection, neutropenia, anemia, thrombocytopenia, and deep vein thrombosis/pulmonary embolism. Based on the results of the FIRST study, Celgene Corporation has submitted Revlimid plus dexamethasone to the U.S. Food and Drug Administration for approval for the treatment of patients with NDMM.
Revlimid plus dexamethasone safe and effective for newly diagnosed multiple myeloma.
Celgene Corporation has announced that data from FIRST (MM-020/IFM 07-01) - an open-label phase III randomized study of continuous REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma (NDMM) who are not candidates for stem cell transplant - have been published in the New England Journal of Medicine.
Initial findings, including that the trial had met its primary endpoint of progression free survival (PFS), were reported during the plenary session at the 55th American Society of Hematology annual meeting in December 2013.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy